A phase III , open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies
Journal of Inherited Metabolic Disease · 2025-01 · 48 (1)
DOI: 10.1002/jimd.12795 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 09.10.2024. Verfasst von Myrl Holida und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Genetics and Genomics, Stead Family Department of Pediatrics, University of Iowa, Iowa City, Iowa, USA. Hauptthemen laut MEDLINE: alpha-Galactosidase, Enzyme Replacement Therapy, Fabry Disease, Recombinant Proteins. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Protalix Biotherapeutics.
Abstract (Originalsprache)
Pegunigalsidase alfa, a PEGylated α‐galactosidase A enzyme replacement therapy (ERT) for Fabry disease, has a longer plasma half‐life than other ERTs administered intravenously every 2 weeks (E2W). BRIGHT (NCT03180840) was a phase III, open‐label study in adults with Fabry disease, previously treated with agalsidase alfa or beta E2W for ≥3 years, who switched to 2 mg/kg pegunigalsidase alfa every 4 weeks (E4W) for 52 weeks. Primary objective assessed safety, including number of treatment‐emergent adverse events (TEAEs). Thirty patients were enrolled (24 males); 23 previously received agalsidase beta. Pegunigalsidase alfa plasma concentrations remained above the lower limit of quantification throughout the 4‐week dosing interval. Thirty‐three of 182 TEAEs (in 9 patients) were considered treatment‐related; all were mild/moderate. No patients developed de novo anti‐drug antibodies (ADAs). In the efficacy analysis ( n = 29), median (inter‐quartile range) eGFR change from baseline over 52 weeks was −1.9 (−5.9; 1.8) mL/min/1.73 m 2 ( n = 28; males [ n = 22]: –2.4 [−5.2; 3.2]; females [ n = 6]: −0.7 [−9.2; 2.0]). Overall, median eGFR slope was –1.9 (−8.3; 1.9) mL/min/1.73 m 2 /year (ADA‐negative [ n = 20]: −1.2 [−6.4; 2.6]; ADA‐positive [ n = 9]: −8.4 [−11.6; –1.0]). Lyso‐Gb3 concentrations were low and stable in females, with a slight increase in males (9/24 ADA‐positive). The BRIGHT study results suggest that 2 mg/kg pegunigalsidase alfa E4W is tolerated well in stable adult patients with Fabry disease. Due to the low number of patients in this study, more research is needed to demonstrate the effects of pegunigalsidase alfa given E4W. Further evidence, outside of this clinical trial, should be factored in for physicians to prolong the biweekly ERT intervals to E4W. Take‐home message Treatment with 2 mg/kg pegunigalsidase alfa every 4 weeks could offer a new treatment option for patients with Fabry disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Genetics and Genomics, Stead Family Department of Pediatrics, University of Iowa, Iowa City, Iowa, USA.
- Charles University, General University Hospital, Prague, Czech Republic.
- Department of Public Health, University Federico II of Naples, Naples, Italy.
- Pediatrics Medical Genetics, University of Utah, Salt Lake City, Utah, USA.
- Antwerp University Hospital UZA, Edegem, Belgium.
- Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, Virginia, USA.
ORCID-Profile: John A Bernat
Förderung
- Protalix Biotherapeutics
Zitieren
APA
Holida, M., Linhart, A., Pisani, A., Longo, N., Eyskens, F., Goker-Alpan, O., Wallace, E., Deegan, P., Tøndel, C., Feldt-Rasmussen, U., Hughes, D., Sakov, A., Rocco, R., Almon, E. B., Alon, S., Chertkoff, R., Warnock, D. G., Waldek, S., Wilcox, W. R., & Bernat, J. A. (2025). A phase III , open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. Journal of Inherited Metabolic Disease, 48(1). https://doi.org/10.1002/jimd.12795
Vancouver
Holida M, Linhart A, Pisani A, Longo N, Eyskens F, Goker-Alpan O, et al. A phase III , open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. Journal of Inherited Metabolic Disease. 2025;48(1). doi:10.1002/jimd.12795
BibTeX
@article{Holida2025,
author = {Holida, Myrl and Linhart, Aleš and Pisani, Antonio and Longo, Nicola and Eyskens, François and Goker-Alpan, Ozlem and Wallace, Eric and Deegan, Patrick and Tøndel, Camilla and Feldt-Rasmussen, Ulla and Hughes, Derralynn and Sakov, Anat and Rocco, Rossana and Almon, Einat Brill and Alon, Sari and Chertkoff, Raul and Warnock, David G and Waldek, Stephen and Wilcox, William R and Bernat, John A},
title = {A phase III , open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies},
journal = {Journal of Inherited Metabolic Disease},
year = {2025},
volume = {48},
number = {1},
doi = {10.1002/jimd.12795}
}
EUVIMED